RVX 208   Click here for help

GtoPdb Ligand ID: 7034

Synonyms: QC-216 | RVX-000222 | RVX-208
PDB Ligand
Compound class: Synthetic organic
Comment: RVX 208 is a derivative of the plant polyphenol resveratrol. RVX 208 is an investigational antagonist of BET bromodomain containing proteins, with potential anti-atherosclerotic action for the treatment of cardiovascular disease (CVD) [2-3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 93.67
Molecular weight 370.15
XLogP 3.86
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCCOc1c(C)cc(cc1C)c1nc(=O)c2c([nH]1)cc(cc2OC)OC
Isomeric SMILES OCCOc1c(C)cc(cc1C)c1nc(=O)c2c([nH]1)cc(cc2OC)OC
InChI InChI=1S/C20H22N2O5/c1-11-7-13(8-12(2)18(11)27-6-5-23)19-21-15-9-14(25-3)10-16(26-4)17(15)20(24)22-19/h7-10,23H,5-6H2,1-4H3,(H,21,22,24)
InChI Key NETXMUIMUZJUTB-UHFFFAOYSA-N
References
1. Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J et al.. (2010)
RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.
J Am Coll Cardiol, 55 (23): 2580-9. [PMID:20513599]
2. Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R, Wu J, McLure KG, Hansen HC, Wagner GS et al.. (2014)
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
Atherosclerosis, 236 (1): 91-100. [PMID:25016363]
3. McLure KG, Gesner EM, Tsujikawa L, Kharenko OA, Attwell S, Campeau E, Wasiak S, Stein A, White A, Fontano E et al.. (2013)
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
PLoS ONE, 8 (12): e83190. [PMID:24391744]
4. McNeill E. (2010)
RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases.
Curr Opin Investig Drugs, 11 (3): 357-64. [PMID:20178050]
5. Nicholls SJ, Gordon A, Johannson J, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJ, Wong NC, Borgman MR, Nissen SE. (2012)
ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.
Cardiovasc Drugs Ther, 26 (2): 181-7. [PMID:22349989]
6. Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H et al.. (2013)
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Proc Natl Acad Sci USA, 110 (49): 19754-9. [PMID:24248379]